Ascentage Pharma Group International - Unsponsored ADR AAPG
14.86
(0.37)
(2.43%)
as of 25 Sep
- Market cap
- $1.4B
- P/E
- —
Follow AAPG
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | |
|---|---|---|---|---|
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
P/Operating CF |
0.00 | 0.00 | 0.00 | 0.00 |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Sales |
0.00 | 0.00 | 0.00 | 0.00 |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
0.21 | 0.00 | 0.00 | 0.00 |
EV/FCF |
0.20 | 0.00 | 0.00 | 0.00 |
Quick Ratio |
1.66 | 1.15 | 1.33 | — |
Current Ratio |
1.79 | 1.26 | 1.44 | — |
Net Debt/EBITDA |
0.44 | (1.64) | (0.93) | 0.00 |
Debt/Assets |
49.95% | 63.74% | 71.81% | 0.00% |
Debt/Equity |
1.48 | 6.09 | 25.42 | — |
Asset Turnover |
0.18 | 0.38 | 0.18 | 0.00 |
Operating CF/Net income |
0.94 | 0.27 | 0.78 | 0.00 |
Capex/Depreciation |
(0.36) | (0.30) | (0.70) | — |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 |
| (155.65%) | (234.96%) | 0.00% | 0.00% | |
| (38.41%) | (15.81%) | (74.04%) | 0.00% | |
ROIC |
(87.57%) | (30.31%) | (67.80%) | 0.00% |
Return on Tangible Assets |
(59.69%) | (35.04%) | (70.35%) | 0.00% |
Average Days of Receivables |
160.81 | 30.94 | 239.89 | 0.00 |
Research and Development Expense of Revenue |
198.12% | 96.59% | 318.48% | 0.00% |
Selling, General and Administrative Expense of Revenue |
104.49% | 39.07% | 169.59% | 0.00% |
Intangible Assets out of Total Assets |
0.02 | 0.04 | 0.04 | 0.00 |
Share Based Compensation of Revenue |
3.64% | 2.13% | 14.19% | 0.00% |
Graham Net Nets |
0.00 | 0.00 | 0.00 | 0.00 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow Yield |
0.00% | 0.00% | 0.00% | 0.00% |
Revenue per Share |
0.92 | 1.78 | 0.43 | 0.47 |
Operating CF per Share |
(1.89) | (0.20) | (1.42) | 0.00 |
Capex per Share |
(0.04) | (0.04) | (0.11) | 0.00 |
Free Cash Flow per Share |
(1.93) | (0.25) | (1.53) | 0.00 |
Cash per Share |
3.97 | 2.29 | 2.13 | 0.00 |
Shareholders Equity per Share |
2.14 | 0.50 | 0.14 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.14 | 0.50 | 0.14 | 0.00 |
Free Cash Flow |
(171.84) | (18.58) | (107.73) | — |
Working Capital |
186.01 | 42.13 | 56.42 | — |
Capital Expenditures |
(3.94) | (3.33) | (7.82) | — |
Net Current Asset Value |
45.02 | (119.12) | (149.38) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.05 | 0.02 | 0.26 | 0.00 |
Net Profit Margin |
(216.47%) | (41.34%) | (416.98%) | (421.02%) |
| Other line items | ||||
Depreciation/Fixed assets |
0.10 | 0.10 | 0.09 | — |
Cash ROIC |
(33.81%) | (29.99%) | (55.13%) | — |
Accounts Receivable Turnover |
3.45 | 8.54 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.50 | 0.35 | 0.00 | — |
Inventory Turnover |
2.80 | 2.55 | 0.00 | — |
Average Days of Payables |
796.14 | 1,154.28 | 865.74 | — |
Days of Inventory on Hand |
213.43 | 82.82 | 193.23 | — |
Average Receivables |
23.78 | 15.73 | — | — |
Average Payables |
13.93 | 11.28 | — | — |
Average Inventory |
2.50 | 1.56 | — | — |
Average Assets |
462.71 | 351.35 | 172.03 | — |
Average Common Equity |
114.17 | 23.64 | — | — |
Columns are period end dates